[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639485":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":25,"locations":30,"responsibleParty":53,"collaborators":25,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":25,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":25,"studyType":70,"phases":71,"briefSummary":74,"conditions":75,"keywords":25,"overallStatus":33,"whyStopped":25,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Control group","ACTIVE_COMPARATOR","35 patients will receive Sertraline 50 mg\u002Fday plus a placebo.",[13],"Drug: Sertraline 50 MG",{"label":15,"type":10,"description":16,"interventionNames":17},"Allopurinol group","35 patients will receive 50 mg\u002Fday of sertraline plus allopurinol (300 mg\u002Fday).",[13,18],"Drug: Allopurinol 300 MG",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Sertraline 50 MG","Sertraline is an antidepressant medication of the selective serotonin reuptake inhibitor class used to treat major depressive disorder, generalized anxiety disorder, social anxiety disorder, obsessive-compulsive disorder, panic disorder, and premenstrual dysphoric disorder.",[15,9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Allopurinol 300 MG","Allopurinol is a potent inhibitor of the enzyme xanthine oxidase and is primarily used to treat hyperuricemia and gout",[15],[31],{"facility":32,"status":33,"city":34,"state":25,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Tanta Unuversity","RECRUITING","Tanta","31527","Egypt","EG",{"type":39,"coordinates":40},"Point",[41,42],31.00192,30.78847,{"lat":42,"lon":41},[45,50],{"name":46,"role":47,"phone":48,"phoneExt":25,"email":49},"Mostafa M I Bahaa, PhD","CONTACT","0201025538337","mbahaa@horus.edu.eg",{"name":51,"role":52,"phone":25,"phoneExt":25,"email":25},"Mostafa M Bahaa, PhD","SUB_INVESTIGATOR",{"type":54,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Mostafa Bahaa","Lecturer","100639485","phase-2-allopurinol-in-depression-100639485",false,"NCT07574060","Allopurinol in Depression","Allopurinol Adjuvant Therapy in Patients With Major Depressive Disorder","Inclusion Criteria:\n\nPatients aged greater than 18 years old. Patients with a HAM-D score of at least 10 with item 1, depressed mood, scoring 2 or greater, are eligible.\n\nExclusion Criteria:\n\nPatients with bipolar I or bipolar II disorder Patients with eating disorders Pregnant women or women not using medically accepted means of birth control Cardiovascular disorders Severe renal impairment","ALL","18 Years","60 Years",{"count":68,"type":69},70,"ESTIMATED","INTERVENTIONAL",[72,73],"PHASE2","PHASE3","Major depressive disorder (MDD) is one of the most common psychiatric disorders with serious socioeconomic consequences on daily life and health care costs. Despite the advent of newer antidepressants that target monoamine pathways, nearly 50% of patients have no response to first-line antidepressant therapy. Thus, a combination of medications with different strategies at the beginning of treatment could provide further therapeutic benefits to MDD patients.",[76],"Depression","2026-08-16",{"date":79,"type":80},"2026-08-18","ACTUAL",{"date":82,"type":80},"2026-05-20",{"date":84,"type":69},"2027-05-20",{"name":5,"class":6},1]